Terms: = Leukemia AND MAX, MGC36767, 4149, ENSG00000125952, MGC18164, MGC10775, P61244, MGC11225, orf1, MGC34679 AND Prognosis
15 results:
1. MLPA in the initial genetic screening of patients with acute myeloid leukemia.
Yahya D; Hachmeriyan M; Ruseva T; Chervenkov T; Micheva I
Rom J Intern Med; 2024 Mar; 62(1):44-51. PubMed ID: 37948316
[TBL] [Abstract] [Full Text] [Related]
2. A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia.
Jonas BA; Hou JZ; Roboz GJ; Alvares CL; Jeyakumar D; Edwards JR; Erba HP; Kelly RJ; Röllig C; Fiedler W; Brackman D; Siddani SR; Chyla B; Hilger-Rolfe J; Watts JM
Hematol Oncol; 2023 Oct; 41(4):743-752. PubMed ID: 37086447
[TBL] [Abstract] [Full Text] [Related]
3. MYCMI-7: A Small MYC-Binding Compound that Inhibits MYC: max Interaction and Tumor Growth in a MYC-Dependent Manner.
Castell A; Yan Q; Fawkner K; Bazzar W; Zhang F; Wickström M; Alzrigat M; Franco M; Krona C; Cameron DP; Dyberg C; Olsen TK; Verschut V; Schmidt L; Lim SY; Mahmoud L; Hydbring P; Lehmann S; Baranello L; Nelander S; Johnsen JI; Larsson LG
Cancer Res Commun; 2022 Mar; 2(3):182-201. PubMed ID: 36874405
[TBL] [Abstract] [Full Text] [Related]
4. Inhibition of USP1 reverses the chemotherapy resistance through destabilization of max in the relapsed/refractory B-cell lymphoma.
Li XY; Wu JC; Liu P; Li ZJ; Wang Y; Chen BY; Hu CL; Fei MY; Yu PC; Jiang YL; Xu CH; Chang BH; Chen XC; Zong LJ; Zhang JY; Fang Y; Sun XJ; Xue K; Wang L; Chen SB; Jiang SY; Gui AL; Yang L; Gu JJ; Yu BH; Zhang QL; Wang L
Leukemia; 2023 Jan; 37(1):164-177. PubMed ID: 36352191
[TBL] [Abstract] [Full Text] [Related]
5. Patient characteristics that predict Richter's transformation in patients with chronic lymphocytic leukemia treated with ibrutinib.
Kittai AS; Huang Y; Beckwith KA; Bhat SA; Bond DA; Byrd JC; Goldstein D; Grever MR; Miller C; Rogers KA; Yano M; Woyach JA
Am J Hematol; 2023 Jan; 98(1):56-65. PubMed ID: 36216791
[TBL] [Abstract] [Full Text] [Related]
6. PET/CT Evaluation of the Effect of Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of T-Cell Lymphoblastic Lymphoma.
Zhao J; Guo X; Ma L; Zheng M; Guan T; Su L
Contrast Media Mol Imaging; 2022; 2022():6057017. PubMed ID: 36072622
[TBL] [Abstract] [Full Text] [Related]
7. Clinicians' Understanding of Preferences and Values of People with Hematological Malignancies at the End of Life: Concurrent Surveys.
Button E; Cardona M; Huntley K; Gavin NC; LeBlanc TW; Olsen A; Smith M; Yates P
J Palliat Med; 2022 Sep; 25(9):1386-1397. PubMed ID: 35443803
[No Abstract] [Full Text] [Related]
8. Incubation of Immune Cell Grafts With max.16H5 IgG1 Anti-Human CD4 Antibody Prolonged Survival After Hematopoietic Stem Cell Transplantation in a Mouse Model for Fms Like Tyrosine Kinase 3 Positive Acute Myeloid leukemia.
Hilger N; Mueller C; Stahl L; Mueller AM; Zoennchen B; Dluczek S; Halbich C; Wickenhauser C; Gerloff D; Wurm AA; Behre G; Kretschmer A; Fricke S
Front Immunol; 2018; 9():2408. PubMed ID: 30405611
[TBL] [Abstract] [Full Text] [Related]
9. Economic evaluation of rituximab in addition to standard of care chemotherapy for adult patients with acute lymphoblastic leukemia.
Nam J; Milenkovski R; Yunger S; Geirnaert M; Paulson K; Seftel M
J Med Econ; 2018 Jan; 21(1):47-59. PubMed ID: 28837377
[TBL] [Abstract] [Full Text] [Related]
10. c-Myc-mediated repression of miR-15-16 in hypoxia is induced by increased HIF-2α and promotes tumor angiogenesis and metastasis by upregulating FGF2.
Xue G; Yan HL; Zhang Y; Hao LQ; Zhu XT; Mei Q; Sun SH
Oncogene; 2015 Mar; 34(11):1393-406. PubMed ID: 24704828
[TBL] [Abstract] [Full Text] [Related]
11. Preliminary findings of a 4-month intrahospital exercise training intervention on IGFs and IGFBPs in children with leukemia.
Ruiz JR; Fleck SJ; Vingren JL; Ramírez M; Madero L; Fragala MS; Kraemer WJ; Lucia A
J Strength Cond Res; 2010 May; 24(5):1292-7. PubMed ID: 20224453
[TBL] [Abstract] [Full Text] [Related]
12. ZAP-70 expression, as detected by immunohistochemistry on bone marrow biopsies from early-phase CLL patients, is a strong adverse prognostic factor.
Zanotti R; Ambrosetti A; Lestani M; Ghia P; Pattaro C; Remo A; Zanetti F; Stella S; Perbellini O; Prato G; Guida G; Caligaris-Cappio F; Menestrina F; Pizzolo G; Chilosi M
Leukemia; 2007 Jan; 21(1):102-9. PubMed ID: 17082778
[TBL] [Abstract] [Full Text] [Related]
13. Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia.
Roman-Gomez J; Jimenez-Velasco A; Agirre X; Cervantes F; Sanchez J; Garate L; Barrios M; Castillejo JA; Navarro G; Colomer D; Prosper F; Heiniger A; Torres A
Oncogene; 2005 Nov; 24(48):7213-23. PubMed ID: 16170379
[TBL] [Abstract] [Full Text] [Related]
14. N-myc oncogene overexpression down-regulates leukemia inhibitory factor in neuroblastoma.
Hatzi E; Murphy C; Zoephel A; Ahorn H; Tontsch U; Bamberger AM; Yamauchi-Takihara K; Schweigerer L; Fotsis T
Eur J Biochem; 2002 Aug; 269(15):3732-41. PubMed ID: 12153570
[TBL] [Abstract] [Full Text] [Related]
15. max protein expression is associated with survival of children with lymphoblastic lymphoma.
Yuza Y; Kawakami M; Takagi K; Yamazaki Y; Urashima M
Pediatr Int; 1999 Dec; 41(6):637-40. PubMed ID: 10618883
[TBL] [Abstract] [Full Text] [Related]
